Are Compounded GLP-1 Medications at Real Risk?

Understanding the risks associated with compounded GLP-1 medications.

Risks of Compounded GLP-1 Medications

Compounded GLP-1 medications, while potentially appealing for some patients, carry significant risks. The primary concern is that these compounded versions may not be subject to the same rigorous testing and quality control as FDA-approved medications. This can lead to variations in potency, purity, and safety, which can pose serious health risks.

Additionally, there is a notable risk of counterfeit products in the market. Many individuals have reported issues with gray-market 'research' peptides or unverified online sources selling semaglutide. These counterfeits can contain incorrect dosages or harmful substances, leading to adverse health outcomes.

Safety and Regulation

GLP-1 medications, including those that are compounded, are prescription drugs that come with real risks. For example, orforglipron (Foundayo) and other GLP-1 medications carry a boxed warning for thyroid C-cell tumors and are contraindicated for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).

It is crucial for patients to consult with a licensed clinician regarding any GLP-1 medication, including compounded versions, to ensure safety and appropriateness for their specific health needs.